- Field Trip Health has announced that the U.S. Patent and Trademark Office (USPTO) has granted the company a patent for claims related to FT-104 (informally known as “Isoprocin Glutarate”)
- This is Field Trip’s first novel psychedelic molecule in development
- Claims in the patent application grant exclusive rights to Field Trip for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104
- The patent will provide protection until 2040
- A protocol has been submitted for ethics review
- Field Trip Health Limited (FTRP) opened trading today at $1.57
Field Trip Health (FTRP) has been granted a patent for claims related to FT-104.
The patent was granted by the U.S. Patent and Trademark Office (USPTO).
This is Field Trip’s first novel psychedelic molecule in development.
Claims in the patent application titled, “Tryptamine Prodrugs,” grant exclusive rights to Field Trip for the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104.
The patent will provide protection until 2040.
As part of its intellectual property strategy, Field Trip filed an international patent application relating to FT-104 under the Patent Cooperation Treaty (PCT).
The PCT filing is a step towards expansion into National Phase filings to protect FT-104 in major markets where Field Trip intends to pursue commercialization, in the event of regulatory approval.
The PCT patent application provides Field Trip with deferred patent filing rights in 150+ countries.
“The US patent grant strengthens IP protection for our lead drug candidate FT-104 for the global pharmaceutical market,” noted Joseph del Moral, CEO of Field Trip.
“We are continuing to strengthen patent protections for FT-104 and its uses across the globe, as we advance our Phase 1 clinical trial and continue to develop other molecules in our pipeline.”
Field Trip’s approach leverages science and best-in-class psychotherapy protocols to inform promising treatment approaches for use in research and clinical applications.
As part of that process, Field Trip has made significant progress toward its phase 1 clinical trial, with advances in its Chemistry-Manufacturing-Control (“CMC”) and nonclinical-safety toxicology programs for FT-104, and expects to initiate a Phase 1 clinical trial before the end of the first half of 2022.
A protocol has been submitted for ethics review.
Field Trip is a global leader in the development and delivery of psychedelic therapies.
Field Trip Health Limited (FTRP) opened trading today at $1.57.
